The program rewards projects that develop new technologies and promote the application of new ideas and technologies arising from collaborations between academia and industry. The other participants in the project are the Oncology-Pathology group from the "http://www.irblleida.cat/ca/index.php?p=webs/investigadors/cercador.php&a=v" IRB of Lleida, led by Dr. Xavier Matias-Guiu, and the companies "http://www.formune.es/" ForMune and "http://www.althia.es/" Althia.The Project, awarded a total of 650.769,80€ of which 107.350€ are for the VHIR group, focuses on the prediction of endometrial cancer recurrence and the design of new therapeutic strategies. The main goal is to find a method to determine the risk of disease recurrence, since identification of patients at high risk is critical for deciding the best therapeutic strategy and for a more rational design of clinical trials. 80% of patients with endometrial cancer have a good prognosis. Even so, it remains among the 10 most fatal cancers for women in developing countries due to its high incidence. Mortality is directly linked to the recurrence risk. Improving global survival and decreasing recurrence depends on the search of reliable biomarkers that permit identification of patients that may relapse. The project proposes to develop a predictive method based on the expression of the ANXA2 protein, and to use it as a tool for optimal categorization of patients susceptible to receiving treatment. Other research groups from VHIR have also received funds from this program. They include the Rheumatology team, led by Dr. Sara Marsal, in the Systemic Diseases group, and the Peripheral Nervous System group, led by Dr. Josep Gamez. The latter "http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&mv1=5&mv2=3&mh1=0&mh2=0&mh3=0&mh4=0&ms=0&any=2014&num=167" received funding for two projects within the same call, something unusual for such a highly competitive program. In all, VHIR has obtained 471.921€ for 4 different research projects in the 2014 call.